ProKidney Corp. (BMV:PROK)

Market Cap	5.71B
Revenue (ttm)	13.65M
Net Income (ttm)	-1.30B
Shares Out	n/a
EPS (ttm)	-9.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,652
Average Volume	28,168
Open	41.30
Previous Close	n/a
Day's Range	40.77 - 41.30
52-Week Range	12.18 - 132.00
Beta	n/a
RSI	42.95
Earnings Date	Mar 18, 2026

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 204
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: PROK

Financial Performance

Financial numbers in USD